AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06238024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Single dose intravenous application
Study NCT06238024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% 100ml
Description: Single dose intravenous application
Study NCT05659147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Research MRI without administration of intravenous secretin
Description: Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
Study NCT05659147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Research MRI with administration of intravenous secretin
Description: Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
Study NCT05659147 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Sequencing
Description: Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
Study NCT05659147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Tests
Description: Research blood draw (for markers of pancreatic endocrine insufficiency)
Study NCT05659147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool Tests
Description: Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
Study NCT05659147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Completion
Description: Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
Study NCT05659147 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic function tests (ePFTs)
Description: At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
Study NCT05659147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin
Description: Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg).~Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI.~Participants in Aim 4 will receive two doses (1 during each MRI).~Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study.
Study NCT05184348 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrow band Ultraviolet B phototherapy group
Description: 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
Study NCT05184348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin group
Description: dose of 0.5-1 mg per kg per day orally for 3 month.
Study NCT05184348 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin plus Narrow band Ultraviolet B phototherapy group
Description: Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
Study NCT05209230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy
Description: Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
Study NCT05209230 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
Study NCT05610488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]
Description: Intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits
Study NCT04819061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS Active
Description: This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
Study NCT04819061 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
Study NCT05357976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
Study NCT05050825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient clinical management based on the CDSA strategy
Description: The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
Study NCT05071638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous cord blood mononuclear cells
Description: preterm neonates less than 28 weeks who suffer BPD and also stored cord blood are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg).
Study NCT05692700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: essential oil application by inhalation
Study NCT05692700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo essential oil
Study NCT06090188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A Culture-Based Multicomponent Cognitive Training Program
Description: Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
Study NCT06090188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Culture-Based Multicomponent Cognitive Training Program
Description: Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
Study NCT05410080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
Description: Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
Study NCT04695405 — intervention group
Intervention type: GENETIC
Intervention: Saliva Genetic Samples
Description: Patients will provide two saliva swabs containing genetic materials.
Study NCT04821557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protease + Protein
Description: Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
Study NCT04821557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Protein
Description: Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
Study NCT06254937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive Life Plan training
Description: Reproductive Life Plan trainings; It will be done in the form of group training, which is considered an advantageous health education method in terms of low cost, wide scope and practicality. During the training, after the power point presentation to the initiative group, question-answer, discussion, brainstorming and visualizations will be made with the Pecha Kucha Technique. Presentations prepared in line with the Reproductive Life Plan Training Booklet will be used as training tools. Training will be given to participants face to face for 40 minutes, once a week for five weeks. Each training session will include two topics in booklet.
Study NCT04743609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nasopharyngeal samples
Description: rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients
Study NCT05104489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: IM injection
Study NCT05104489 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AdimrSC-2f
Description: IM injection
Study NCT05733195 — intervention group
Intervention type: OTHER
Intervention: OGTT test
Description: The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
Study NCT05549284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib,Rituximab and Methotrexate
Description: Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
Study NCT05145283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conestat alfa (Ruconest®)
Description: In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
Study NCT05145283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%)
Description: Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
Study NCT05554497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction curriculum
Description: Standard 8-week mindfulness-based stress reduction curriculum
Study NCT05568134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours.
Study NCT04838847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV Vaccine
Description: Intramuscular (IM) injection
Study NCT05417412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy
Description: 8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
Study NCT04651478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation+Motor Imagery through BCI
Description: Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.
Study NCT04651478 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Action Observation through non-related with movement illustrations
Description: The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
Study NCT05528172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: K-321 ophthalmic solution
Study NCT05528172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution
Study NCT05495321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.
Study NCT05495321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.
Study NCT05262517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg ODT
Study NCT05262517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT06431100 — intervention group
Intervention type: BIOLOGICAL
Intervention: TCR T-cells
Description: The strengthened T cells are re-infused into the patient to achieve the killing effect
Study NCT06514079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal dilatation with steroids injection
Description: Under general anesthesia with the patient in the left lateral position. A single-channel endoscope was used. Endoscopic bougie dilatation was performed using Wire-guided Polyvinyl dilator Savary Gilliard/SG. Long-acting steroids triamcinolone acetonide was injected via 25-gauge sclerotherapy catheter. One mL solution of triamcinolone acetonide 40mg/ml was diluted with one mL of saline, in a 2 mL disposable syringe, and 0.5 mL each was injected at the proximal margin of the stricture in four quadrants, 2 mL solution in four quadrants
Study NCT06444334 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level Diode Laser
Description: Group 2 was exposed to laser irradiation following implant insertion for 3 sessions: Immediately after implant insertion, 2 days after implant insertion and 1 week after insertion , using a red Diode(gallium-aluminun-arsenide) LLLT using calibrated diode laser device
Study NCT06444334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF platelet rich fibrin
Description: The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors
Study NCT06444334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF platelet rich fibrin
Description: The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors
Study NCT04924634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Levels and Mental Well-Being assessment
Description: At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
Study NCT05658471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Research E-Cigarette (SREC)
Description: Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
Study NCT05658471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over the Counter E-Cigarette (EC)
Description: Usual brand e-cigarettes will be provided at the hospital stay.
Study NCT05658471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biological Samples
Description: Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
Study NCT05658471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking-related Questionnaires
Description: Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
Study NCT06336421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: VR Box brand virtual reality glasses were used in primiparous pregnant women undergoing cesarean section.~During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes.
Study NCT04912453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary anastomosis
Description: At laparotomy, the diseased segment of intestine will be resected and the patients will then receive primary anastomosis
Study NCT04912453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enterostomy
Description: At laparotomy, the diseased segment of intestine will be resected and the patients will then receive enterostomy